1. Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies 
Rohit K. Katial, MD, Greg W. Bensch, MD, William W. Busse, MD, Bradley E. Chipps, MD, Joshua L. Denson, MD, Anthony N. Gerber, MD, PhD, Joshua S. Jacobs, MD, Monica Kraft, MD, Richard J. Martin, MD, Parameswaran Nair, MD, PhD, FRCP, FRCPC, Michael E. Wechsler, MD 
The Journal of Allergy and Clinical Immunology: In Practice 
Volume 5, Issue 2, Pages S1-S14 (March 2017)
DOI: /j.jaip
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Figure 1
Pathobiology of airway inflammation in asthma. LT, Leukotriene; MMP, matrix metalloproteinase; NE, neutrophil elastase; ROS, reactive oxygen species; TSLP, thymic stromal lymphopoietin.
Reproduced from Pelaia et al34 under the Creative Commons Attribution License.
The Journal of Allergy and Clinical Immunology: In Practice 2017 5, S1-S14DOI: ( /j.jaip )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Figure 2
Important type 2-inflammation targets for biologic therapies. TSLP, Thymic stromal lymphopoietin.
Adapted with permission from Mitchell et al.57
The Journal of Allergy and Clinical Immunology: In Practice 2017 5, S1-S14DOI: ( /j.jaip )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Figure 3
Traditional and personalized approaches to treating asthma. FeNO, Fractional exhaled nitric oxide; Hx, history; ICS, inhaled corticosteroid; IgE, immunoglobulin E, LABA, long-acting β-agonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β-agonist.
Adapted with permission from Dunn et al.96
The Journal of Allergy and Clinical Immunology: In Practice 2017 5, S1-S14DOI: ( /j.jaip )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions